Click HERE to register.

Join Margaret von Mehren, MD and Prof. Jean-Yves Blay, MD for this live web broadcast, as they dive into the pathobiology of this malignancy and discuss the latest data for newly approved and emerging agents to offer guidance on adopting modern targeted strategies to improve outcomes across multiple lines of therapy. The panel will also share case vignettes and patient stories illustrating the practical aspects of multidisciplinary care throughout the treatment journey.

Join Us for One of Two Web Broadcasts

• Friday, November 20, 2020: 3:00–4:00 PM EST (This event is being held in conjunction with the CTOS Virtual Annual Meeting)
• Thursday, December 3, 2020: 7:00–8:00 PM EST

Activity Description

Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. Our understanding of the pathogenesis of GIST was revolutionized by the discovery of KIT and PDGFRA mutations, which provided a diagnostic criteria and expanded treatment options. Tyrosine kinase inhibitors (TKIs) imatinib, sunitinib, and regorafenib are the recommended first 3 lines of therapy for most patients; however, tumor responses remain suboptimal, in part, because of resistance mutations associated with TKI therapy. With the goal to overcome treatment resistance and prolong life, research on modern TKIs has led to the approvals of avapritinib and ripretinib. Modern TKIs are also transforming the therapeutic algorithm for patients with unresectable/metastatic GIST.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, pediatric oncologists, advanced practice clinicians, pathologists, and other clinicians involved in the care of patients with GIST.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Describe the pathobiology, including recurrence patterns and molecular/mutational features, of unresectable/metastatic GIST
• Assess emerging and newly validated evidence on targeted TKI options for patients with GIST along multiple lines of treatment
• Develop safe and effective therapeutic algorithms with modern TKIs based on molecular status, prior treatment history, and patient-centered factors
• Plan management strategies associated with the use of modern TKIs in the GIST setting

Faculty

Chair

Margaret von Mehren, MD
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Presenters

Prof. Jean-Yves Blay, MD
Centre Léon Bérard
Lyon, France

Suzanne George, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Accreditation

The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.